Menu
/REGISTER
Montecito
Nixon Peabody
SBCC
BOL
Bank of America
Loading...
You are here:  Home  >  Health Care  -  Page 60
Latest

FDA to review Amgen’s new kidney disease dug

By   /  Friday, November 6th, 2015  /  East Ventura County, Health Care, Latest news  /  Comments Off on FDA to review Amgen’s new kidney disease dug

Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →

Read More →
Latest

Goleta’s Sientra reassures investors, surgeons

By   /  Friday, November 6th, 2015  /  Health Care, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Goleta’s Sientra reassures investors, surgeons

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen’s third quarter earnings beat Wall Street expectations

By   /  Wednesday, October 28th, 2015  /  Health Care, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen’s third quarter earnings beat Wall Street expectations

Thousand Oaks biotech giant Amgen blew Wall Street away when it released third quarter earnings on Oct. 28. Amgen beat analyst revenue estimates by posting revenues of $5.72 billion, compared to the $5.23 billion analysts expected. That’s up from about $5 billion during last year’s third quarter. Net income increased to $1.86 billion during the Read More →

Read More →
Latest

Sientra CEO ducks questions about company’s future

By   /  Wednesday, October 28th, 2015  /  Health Care, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Sientra CEO ducks questions about company’s future

Sientra CEO Hani Zeini said in a conference call on Oct. 28 that he will not speculate about the company’s future. Zeini dodged questions better than a Brooklyn Dodger dodges street cars during the call with investors, analysts and reporters to update all parties about implants contaminated by Sientra’s manufacturer. Sientra shares nosedived on Sept. Read More →

Read More →
Latest

FDA OKs Amgen skin cancer drug Imlygic

By   /  Tuesday, October 27th, 2015  /  Health Care, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on FDA OKs Amgen skin cancer drug Imlygic

The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →

Read More →
Latest

Fire breaks out at Sientra manufacturer

By   /  Friday, October 23rd, 2015  /  Health Care, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Fire breaks out at Sientra manufacturer

Goleta breast implant developer Sientra said there had been a fire at the factory of its manufacturer in Brazil, the company announced on Oct. 23. Sientra did not say how big the fire was or if it would impact manufacturing at Silimed, the largest producer of silicone implants in South America. The company didn’t specify Read More →

Read More →
Latest

Sientra waits for production to resume amid stock crash

By   /  Friday, October 23rd, 2015  /  Health Care, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Sientra waits for production to resume amid stock crash

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →